摘要
目的:探讨P53、PS2在新辅助化疗中的化疗敏感性的预测价值。方法:对135例乳腺癌患者化疗前经空芯针穿刺,经免疫组化确定P53、PS2表达情况。结果:4~6个周期的密集新辅助化疗后有完整化疗评价结果135例,化疗总有效率76.3%;P53阳性79例、P53阴性56例,化疗有效率分别为81.01%、69.64%;PS2阳性65例、PS2阴性70例,化疗有效率分别为72.31%、80.00%;P53、PS2表达情况与化疗疗效评价差异无统计学意义。结论:P53、PS2表达与新辅助化疗敏感性无明显相关性,不能作为新辅助化疗疗效的敏感因子。
Objective:To evaluate the predictive value of the chemotherapy sensitivity of PS2 and P53 in neoadjuvant chemotherapy.Methods:The expression of P53 and PS2 in 135 patients with breast cancer before the chemotherapy were determined by hollow needle aspiration,immunohistochemistry.Results:After 4~6 cycles of intensive neoadjuvant chemotherapy,a complete evaluation of chemotherapy results in 135 cases,the overall response rate was 76.3%,79 cases were positive for P53,P53 negative in 56 cases,the effective rate of chemotherapy was 81.01%,69.64% respectively;65 cases were positive for PS2 and PS2 negative in 70 cases,the effective rate of chemotherapy was 72.31%,80.00% respectively;P53 and PS2 expression and evaluation of curative effect of chemotherapy had no statistical significance.Conclusion:There was no significant correlation between the expression of P53 and PS2 and the sensitivity to neoadjuvant chemotherapy,which could not be used as a new adjuvant chemotherapy effect.
出处
《中国社区医师》
2016年第27期117-118,共2页
Chinese Community Doctors